11 results about "Castration Resistance" patented technology

This is a method for treating prostate cancer. Specifically, it involves the use of the compound shown in Formula I or a pharmaceutically acceptable salt thereof in the manufacture of a drug for treating metastatic castration-resistant prostate cancer. [Formula 1] JPEG2026521901000005.jpg32155

The application belongs to the technical field of biological medicine, and discloses application of a MYLK3 gene inhibitor in preparation of a drug for treating castration-resistant prostate cancer. The biological function of MYLK3 in prostate cancer is confirmed for the first time, an intervention means with the gene as a target point is provided, and it is confirmed that the MYLK3 inhibitor can improve the sensitivity of castration-resistant prostate cancer to androgen receptor antagonists. A gene therapy drug with the human MYLK3 gene as a treatment target point is specially provided, which is suitable for the treatment of prostate cancer (especially castration-resistant prostate cancer), and can also be combined with other targeted drugs to improve the treatment effect. By designing a reasonable RNAi target sequence for the target gene, a retrovirus vector plasmid containing the target sequence is successfully constructed, which has a significant inhibitory effect on the proliferation ability of prostate cancer cells, and significantly increases the sensitivity of prostate cancer cells to AR antagonists.

The present invention relates to methods for predicting the progression of prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC), in an individual. The invention employs gene expression profiling combined with predictive modeling to assess the likelihood of overall survival and biochemical recurrence following treatment.

Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and / or activity.

The present disclosure discloses application of PRDX5 and GPX4 genes in preparation of drugs for castration-resistant prostate cancer and belongs to the technical field of biological medicines. The present disclosure proposes that silencing or interfering with the expression of the PRDX5 and / or GPX4 genes can be used in the treatment or adjuvant treatment of castration-resistant prostate cancer. The present disclosure proposes for the first time a new strategy for preparing the drugs for the treatment of CRPC using siRNA in combination with an androgen receptor antagonist. The pharmaceutical composition comprising siRNA in combination with an androgen receptor antagonist according to the present disclosure can be used for the treatment of castration-resistant prostate cancer and significantly improves the inhibitory effect of enzalutamide on castration-resistant prostate cancer, which provides the basis for the design and clinical application of nucleic acid drugs with important clinical therapeutic significance.

The present invention discloses the use of stachyose in the preparation of a drug for treating castration-resistant prostate cancer, which belongs to the field of biomedicine. The present invention is the first to propose a new strategy for combining stachyose with androgen receptor antagonists to prepare a drug for treating CRPC, and conducts multifaceted and multi-stage validation research. The pharmaceutical composition of the present invention combining stachyose with androgen receptor can be used to treat castration-resistant prostate cancer, which can significantly improve the inhibitory effect of enzalutamide on castration-resistant prostate cancer, and the application of natural compounds to late-stage cancer is of great significance in clinical treatment.

Masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of metastatic castrate-resistant prostate cancer (mCRPC) in a subject in need thereof. In particular, masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of mCRPC in a subject suffering from early mCRPC associated (i) with alkaline phosphatase (ALP) levels at baseline equal to or lower than 250 IU / L, or (ii) with a Halabi prognosis score (H) at baseline equal to or lower than 33, or (iii) with ALP levels at baseline equal to or lower than 250 IU / L and with a Halabi prognosis score (H) at baseline equal to or lower than 33.

The invention relates to the field of therapeutic antibodies for the treatment of a subject with castration-resistant prostate cancer. More in particular it relates to treating castration-resistant prostate cancer using a bispecific antibody that comprises an antigen binding site that can bind an extracellular part of ERBB2 and an antigen binding site that can bind an extracellular part of ERBB3. Also, it relates to treating castration-resistant prostate cancer using an antibody that comprises an antigen binding site that can bind an extracellular part of ERBB3. The invention also relates to treating castration-resistant prostate cancer using a combination of one of said antibodies and an androgen receptor axis-targeting agent.

Provided is a novel method for treating CRPC, particularly, CRPC which has acquired resistance to an antiandrogen agent. The present invention relates to an antitumor agent wherein 3-ethyl-4-{4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide or a salt thereof and an antiandrogen agent are administered in combination.